3 IMvigor 210
First-line maintenance treatment: JAVELIN Bladder 100
5
Given the above success of immunotherapy in bladder cancer, there is great interest in the possibility of moving immunotherapy into the neoadjuvant disease space. Currently, there are many ongoing clinical trials for neoadjuvant immunotherapy:
6
7 and ABACUS
8 phase II trials. PURE-01 enrolled 143 patients that were treated with 3 cycles of pembrolizumab, resulting in a pT0 rate of 37%. ABACUS enrolled 95 patients that were treated with two cycles of atezolizumab, resulting in a pT0 rate of 31%. Three clinical trials have assessed the utility of immunotherapy combination therapy, including the NABUCCO (ipilimumab + nivolumab x 3), DUTRENEO (durvalumab + tremelimumab x 3), and durvalumab + tremelimumab x 2 (NCT02812420). As follows is a summary of these trials:
EAU 2021: Should We Perform PSMA PET/CT in the Initial Staging of Prostate Cancer? A Pro Versus Con Debate
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
EAU 2021: Intraprostatic Recurrences on PSMA PET/CT After Prostate Whole Gland Radiotherapy: Is Histological Confirmation Necessary?
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
EAU 2021: Gaps in the Evidence: Adjuvant Versus Early Salvage Radiotherapy
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.
EAU 2021: Long-Term Validation on the Impact of PSMA-PET on Metastasis-Free Survival in a Large Salvage Radiotherapy Cohort
urotoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from urotoday.com Daily Mail and Mail on Sunday newspapers.